Gavert, Nancy http://orcid.org/0000-0003-1639-4684
Zwang, Yaara
Weiser, Roi
Greenberg, Orli
Halperin, Sharon
Jacobi, Oded
Mallel, Giuseppe
Sandler, Oded
Berger, Adi Jacob
Stossel, Erez
Rotin, Daniil
Grinshpun, Albert http://orcid.org/0000-0002-3351-5719
Kamer, Iris
Bar, Jair
Pines, Guy
Saidian, Daniel
Bar, Ilan
Golan, Shay http://orcid.org/0000-0002-9205-5820
Rosenbaum, Eli
Nadu, Andrei
Ben-Ami, Eytan
Weitzen, Rony
Nechushtan, Hovav
Golan, Talia
Brenner, Baruch
Nissan, Aviram
Margalit, Ofer
Hershkovitz, Dov
Lahat, Guy
Straussman, Ravid http://orcid.org/0000-0002-9476-329X
Funding for this research was provided by:
Rising Tide Translational Cancer Research Fund
Article History
Received: 7 February 2021
Accepted: 10 December 2021
First Online: 10 February 2022
Competing interests
: R.S. and N.G. are founders, stockholders and paid consultants of the company CuResponse, which currently validates EVOC as a predictive biomarker for the effect of anticancer drugs. G.M. worked as a part-time pathologist for Curesponse. E.S. works as a part-time technician at CuResponse. No other potential conflicts of interest were disclosed by other authors.